Antithrombotic Management of Peripheral Artery Disease

General Guideline Recommendations

Current ACC/AHA (2024) and ESC (2024) guidelines advise against the use of oral anticoagulants for PAD when no other indication exists; antiplatelet therapy remains the standard of care (Class I)【@2】.
Single antiplatelet therapy (aspirin 75‑100 mg daily or clopidogrel 75 mg daily) is the cornerstone treatment for symptomatic PAD patients (Class I)【@1】【@3】【@4】.
Combining warfarin with aspirin is recommended against (Grade 1B), and this principle extends to all direct oral anticoagulants (DOACs)【@1】.

Apixaban is not recommended for PAD alone; it should be used only when the patient has a separate indication for anticoagulation (e.g., atrial fibrillation, VTE, mechanical valve)【@1】【@2】.
In patients with PAD and a separate anticoagulation indication, apixaban monotherapy (without added antiplatelet agents) is advised (Class IIb)【@2】.
Routine addition of aspirin or clopidogrel to full‑dose apixaban markedly raises major‑bleeding risk without proven cardiovascular benefit in most PAD patients (Class IIb)【@2】.
Full‑dose apixaban (5 mg BID) should never be prescribed for PAD alone, as it increases bleeding without improving limb or cardiovascular outcomes (Class III)【@2】.

Low‑dose rivaroxaban 2.5 mg twice daily plus aspirin 81‑100 mg daily is the only antithrombotic combination proven to reduce both major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in symptomatic PAD (Class I)【@3】【@2】【@4】.
This regimen is specifically recommended for symptomatic PAD patients and after lower‑extremity revascularization (Class I ACC/AHA 2024)【@3】【@4】.

Apixaban monotherapy at standard AF dosing is the preferred strategy (Class IIb)【@2】.
Short‑term (1‑3 months) single antiplatelet therapy may be added after recent PAD revascularization, then transition to anticoagulation alone (Class IIa)【@2】.

Rivaroxaban 2.5 mg BID + aspirin is recommended to lower MACE and MALE (Class I)【@3】【@4】.
An alternative is continuation of single antiplatelet therapy long‑term (Class I)【@1】【@4】.

Full‑dose anticoagulation (apixaban or any DOAC) combined with antiplatelet therapy for PAD alone is discouraged due to excess bleeding and lack of benefit (Class III)【@2】.
Triple therapy (anticoagulant + dual antiplatelet) should be avoided except for a brief period after acute coronary syndrome, because bleeding risk is prohibitive (Class III)【@2】.
Do not confuse apixaban with low‑dose rivaroxaban; they have distinct indications in PAD management (Class I)【@3】.